Regulating the regulators in cancer-immunosuppression in multiple myeloma (MM)

Blood Reviews

Volumn 27, Issue 3, 2013, Pages 155-164

  Feyler, Sylvia ^a,b   Selby, Peter J ^a   Cook, Gordon ^a,c  

^a UNIVERSITY OF LEEDS   (United Kingdom)

^b CALDERDALE AND HUDDERSFIELD NHS FOUNDATION TRUST   (United Kingdom)

^c LEEDS TEACHING HOSPITALS NHS TRUST   (United Kingdom)

Author keywords

Cancer induced immune suppression; Immunotherapy; Myeloma; Regulatory T cells

Indexed keywords

CANCER VACCINE; DENDRITIC CELL VACCINE; ELOTUZUMAB; FLUDARABINE; INTERLEUKIN 2; SUNITINIB; THALIDOMIDE;

ADOPTIVE TRANSFER; ALLOGENEIC STEM CELL TRANSPLANTATION; ARTICLE; CANCER IMMUNOTHERAPY; CANCER PROGNOSIS; CANCER SURVIVAL; CD4+ CD25+ T LYMPHOCYTE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CHRONIC LYMPHATIC LEUKEMIA; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DENDRITIC CELL; DISEASE FREE SURVIVAL; DONOR LYMPHOCYTE INFUSION; HUMAN; IMMUNE DEFICIENCY; IMMUNE EVASION; IMMUNE RESPONSE; IMMUNOLOGICAL TOLERANCE; KIDNEY METASTASIS; MULTIPLE MYELOMA; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; REGULATORY T LYMPHOCYTE; SUPPRESSOR CELL; TUMOR ASSOCIATED LEUKOCYTE; TUMOR MICROENVIRONMENT;

HUMANS; IMMUNOTHERAPY; MULTIPLE MYELOMA; RESEARCH;

EID: 84877146756     PISSN: 0268960X     EISSN: 15321681     Source Type: Journal    
DOI: 10.1016/j.blre.2013.04.004     Document Type: Article

References (185)

1. Krueger A., Willenzon S., Lyszkiewicz M., Kremmer E., Forster R. CC chemokine receptor 7 and 9 double-deficient hematopoietic progenitors are severely impaired in seeding the adult thymus. Blood Mar 11 2010, 115(10):1906-1912. [Research Support, Non-U.S. Gov't].
2. Godfrey D.I., Kennedy J., Suda T., Zlotnik A. A developmental pathway involving four phenotypically and functionally distinct subsets of CD3-CD4-CD8-triple-negative adult mouse thymocytes defined by CD44 and CD25 expression. J Immunol May 15 1993, 150(10):4244-4252.
3. Carpenter A.C., Bosselut R. Decision checkpoints in the thymus. Nat Immunol Aug 2010, 11(8):666-673. [Research Support, N.I.H., Intramural Review].
4. Sambandam A., Maillard I., Zediak V.P., Xu L., Gerstein R.M., Aster J.C., et al. Notch signaling controls the generation and differentiation of early T lineage progenitors. Nat Immunol Jul 2005, 6(7):663-670. [Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, P.H.S.].
5. Bell J.J., Bhandoola A. The earliest thymic progenitors for T cells possess myeloid lineage potential. Nature Apr 10 2008, 452(7188):764-767. [Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't].
6. Lee W.Y., Moriarty T.J., Wong C.H., Zhou H., Strieter R.M., van Rooijen N., et al. An intravascular immune response to Borrelia burgdorferi involves Kupffer cells and iNKT cells. Nat Immunol Apr 2010, 11(4):295-302. [Research Support, Non-U.S. Gov't].
7. Scott E.W., Simon M.C., Anastasi J., Singh H. Requirement of transcription factor PU.1 in the development of multiple hematopoietic lineages. Science Sep 9 1994, 265(5178):1573-1577. [Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, P.H.S.].
8. Tomita K., Hattori M., Nakamura E., Nakanishi S., Minato N., Kageyama R. The bHLH gene Hes1 is essential for expansion of early T cell precursors. Genes Dev May 1 1999, 13(9):1203-1210. [Research Support, Non-U.S. Gov't].
9. Hosoya T., Kuroha T., Moriguchi T., Cummings D., Maillard I., Lim K.C., et al. GATA-3 is required for early T lineage progenitor development. J Exp Med Dec 21 2009, 206(13):2987-3000. [Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't].
10. Emambokus N., Vegiopoulos A., Harman B., Jenkinson E., Anderson G., Frampton J. Progression through key stages of haemopoiesis is dependent on distinct threshold levels of c-Myb. EMBO J Sep 1 2003, 22(17):4478-4488. [Research Support, Non-U.S. Gov't].
11. Georgopoulos K., Bigby M., Wang J.H., Molnar A., Wu P., Winandy S., et al. The Ikaros gene is required for the development of all lymphoid lineages. Cell Oct 7 1994, 79(1):143-156. [Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, P.H.S.].
12. Sitnicka E., Buza-Vidas N., Ahlenius H., Cilio C.M., Gekas C., Nygren J.M., et al. Critical role of FLT3 ligand in IL-7 receptor independent T lymphopoiesis and regulation of lymphoid-primed multipotent progenitors. Blood Oct 15 2007, 110(8):2955-2964. [Research Support, Non-U.S. Gov't].
13. Muroi S., Naoe Y., Miyamoto C., Akiyama K., Ikawa T., Masuda K., et al. Cascading suppression of transcriptional silencers by ThPOK seals helper T cell fate. Nat Immunol Oct 2008, 9(10):1113-1121. [Research Support, Non-U.S. Gov't].
14. Taniuchi I., Osato M., Egawa T., Sunshine M.J., Bae S.C., Komori T., et al. Differential requirements for Runx proteins in CD4 repression and epigenetic silencing during T lymphocyte development. Cell Nov 27 2002, 111(5):621-633. [Comparative Study Research Support, Non-U.S. Gov't].
15. Gershon R.K., Kondo K. Cell interactions in the induction of tolerance: the role of thymic lymphocytes. Immunology May 1970, 18(5):723-737.
16. Fudenberg H.H. Genetically determined immune deficiency as the predisposing cause of "autoimmunity" and lymphoid neoplasia. Am J Med Sep 1971, 51(3):295-298. [Review].
17. Cunningham A.J. Active suppressor mechanism maintaining tolerance to some self components. Nature Mar 13 1975, 254(5496):143-144.
18. Allison A.C., Denman A.M., Barnes R.D. Cooperating and controlling functions of thymus-derived lymphocytes in relation to autoimmunity. Lancet Jul 17 1971, 2(7716):135-140. [Review].
19. Sakaguchi S., Sakaguchi N., Asano M., Itoh M., Toda M. Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. J Immunol Aug 1 1995, 155(3):1151-1164.
20. Thornton A., Shevach E. CD4+CD25+ immunoregulatory T cells suppress polyclonal T cell activation in vitro by inhibiting interleukin 2 production. J Exp Med 1998, 188(2):287-296.
21. Thornton A., Shevach E. Suppressor effector function of CD4+CD25+ immunoregulatory T cells is antigen nonspecific. J Immunol 2000, 164(1):183-190.
22. Levings M.K., Sangregorio R., Roncarolo M.G. Human cd25(+)cd4(+) t regulatory cells suppress naive and memory T cell proliferation and can be expanded in vitro without loss of function. J Exp Med Jun 4 2001, 193(11):1295-1302.
23. Dieckmann D., Plottner H., Berchtold S., Berger T., Schuler G. Ex vivo isolation and characterization of CD4(+)CD25(+) T cells with regulatory properties from human blood. J Exp Med 2001, 193(11):1303-1310.
24. Baecher-Allan C., Brown J., Freeman G., Hafler D. CD4+ CD25high regulatory cells in human peripheral blood. J Immunol 2001, 167(3):1245-1253.
25. Tai X., Van Laethem F., Pobezinsky L., Guinter T., Sharrow S., Adams A., et al. Basis of CTLA-4 function in regulatory and conventional CD4(+) T cells. Blood 2012, 119(22):5155-5163.
26. Shimizu J., Yamazaki S., Takahashi T., Ishida Y., Sakaguchi S. Stimulation of CD25(+)CD4(+) regulatory T cells through GITR breaks immunological self-tolerance. Nat Immunol Feb 2002, 3(2):135-142.
27. McHugh R.S., Whitters M.J., Piccirillo C.A., Young D.A., Shevach E.M., Collins M., et al. CD4(+)CD25(+) immunoregulatory T cells: gene expression analysis reveals a functional role for the glucocorticoid-induced TNF receptor. Immunity Feb 2002, 16(2):311-323.
28. Wildin R.S., Ramsdell F., Peake J., Faravelli F., Casanova J.L., Buist N., et al. X-linked neonatal diabetes mellitus, enteropathy and endocrinopathy syndrome is the human equivalent of mouse scurfy. Nat Genet Jan 2001, 27(1):18-20.
29. Roncarolo M., Gregori S. Is FOXP3 a bona fide marker for human regulatory T cells?. Eur J Immunol 2008, 38(4):925-927.
30. Liu W., Putnam A.L., Xu-Yu Z., Szot G.L., Lee M.R., Zhu S., et al. CD127 expression inversely correlates with FoxP3 and suppressive function of human CD4+ T reg cells. J Exp Med Jul 10 2006, 203(7):1701-1711.
31. Seddiki N., Santner-Nanan B., Martinson J., Zaunders J., Sasson S., Landay A., et al. Expression of interleukin (IL)-2 and IL-7 receptors discriminates between human regulatory and activated T cells. J Exp Med 2006, 203(7):1693-1700.
32. Simonetta F., Chiali A., Cordier C., Urrutia A., Girault I., Bloquet S., et al. Increased CD127 expression on activated FOXP3+CD4+ regulatory T cells. Eur J Immunol 2010, 40(9):2528-2538.
33. Raimondi G., Shufesky W.J., Tokita D., Morelli A.E., Thomson A.W. Regulated compartmentalization of programmed cell death-1 discriminates CD4+CD25+ resting regulatory T cells from activated T cells. J Immunol Mar 1 2006, 176(5):2808-2816.
34. Duggleby R.C., Shaw T.N., Jarvis L.B., Kaur G., Gaston J.S. CD27 expression discriminates between regulatory and non-regulatory cells after expansion of human peripheral blood CD4+ CD25+ cells. Immunology May 2007, 121(1):129-139.
35. Pandiyan P., Zheng L., Ishihara S., Reed J., Lenardo M.J. CD4(+)CD25(+)Foxp3(+) regulatory T cells induce cytokine deprivation-mediated apoptosis of effector CD4(+) T cells. Nat Immunol Dec 2007, 8(12):1353-1362.
36. Oida T., Xu L., Weiner H.L., Kitani A., Strober W. TGF-beta-mediated suppression by CD4+CD25+ T cells is facilitated by CTLA-4 signaling. J Immunol Aug 15 2006, 177(4):2331-2339.
37. Fallarino F., Grohmann U., Hwang K., Orabona C., Vacca C., Bianchi R., et al. Modulation of tryptophan catabolism by regulatory T cells. Nat Immunol 2003, 4(12):1206-1212.
38. Bodor J., Fehervari Z., Diamond B., Sakaguchi S. ICER/CREM-mediated transcriptional attenuation of IL-2 and its role in suppression by regulatory T cells. Eur J Immunol 2007, 37(4):884-895.
39. Paust S., Lu L., McCarty N., Cantor H. Engagement of B7 on effector T cells by regulatory T cells prevents autoimmune disease. Proc Natl Acad Sci U S A 2004, 101(28):10398-10403.
40. Liu V.C., Wong L.Y., Jang T., Shah A.H., Park I., Yang X., et al. Tumor evasion of the immune system by converting CD4+CD25- T cells into CD4+CD25+ T regulatory cells: role of tumor-derived TGF-beta. J Immunol Mar 1 2007, 178(5):2883-2892.
41. Fu S., Zhang N., Yopp A.C., Chen D., Mao M., Chen D., et al. TGF-beta induces Foxp3+ T-regulatory cells from CD4+CD25- precursors. Am J Transplant Oct 2004, 4(10):1614-1627.
42. Chen W., Jin W., Hardegen N., Lei K.J., Li L., Marinos N., et al. Conversion of peripheral CD4+CD25- naive T cells to CD4+CD25+ regulatory T cells by TGF-beta induction of transcription factor Foxp3. J Exp Med Dec 15 2003, 198(12):1875-1886.
43. Selvaraj R.K., Geiger T.L. A kinetic and dynamic analysis of Foxp3 induced in T cells by TGF-beta. J Immunol Jun 15 2007, 178(12):7667-7677.
44. Fantini M., Becker C., Monteleone G., Pallone F., Galle P., Neurath M. Cutting edge: TGF-beta induces a regulatory phenotype in CD4+CD25- T cells through Foxp3 induction and down-regulation of Smad7. J Immunol 2004, 172(9):5149-5153.
45. Groux H., O'Garra A., Bigler M., Rouleau M., Antonenko S., de Vries J., et al. A CD4+ T-cell subset inhibits antigen-specific T-cell responses and prevents colitis. Nature 1997, 389(6652):737-742.
46. Moore K., de Waal Malefyt R., Coffman R., O'Garra A. Interleukin-10 and the interleukin-10 receptor. Annu Rev Immunol 2001, 19:683-765.
47. Levings M.K., Sangregorio R., Galbiati F., Squadrone S., de Waal Malefyt R., Roncarolo M.G. IFN-alpha and IL-10 induce the differentiation of human type 1 T regulatory cells. J Immunol May 1 2001, 166(9):5530-5539.
48. Kemper C., Chan A.C., Green J.M., Brett K.A., Murphy K.M., Atkinson J.P. Activation of human CD4+ cells with CD3 and CD46 induces a T-regulatory cell 1 phenotype. Nature Jan 23 2003, 421(6921):388-392.
49. Pot C., Jin H., Awasthi A., Liu S., Lai C., Madan R., et al. Cutting edge: IL-27 induces the transcription factor c-Maf, cytokine IL-21, and the costimulatory receptor ICOS that coordinately act together to promote differentiation of IL-10-producing Tr1 cells. J Immunol 2009, 183(2):797-801.
50. Levings M., Gregori S., Tresoldi E., Cazzaniga S., Bonini C., Roncarolo M. Differentiation of Tr1 cells by immature dendritic cells requires IL-10 but not CD25+CD4+ Tr cells. Blood 2005, 105(3):1162-1169.
51. Veldman C., Pahl A., Hertl M. Desmoglein 3-specific T regulatory 1 cells consist of two subpopulations with differential expression of the transcription factor Foxp3. Immunology 2009, 127(1):40-49.
52. Passerini L., Di Nunzio S., Gregori S., Gambineri E., Cecconi M., Seidel M., et al. Functional type 1 regulatory T cells develop regardless of FOXP3 mutations in patients with IPEX syndrome. Eur J Immunol 2011, 41(4):1120-1131.
53. Weiner H.L. Induction and mechanism of action of transforming growth factor-beta-secreting Th3 regulatory cells. Immunol Rev Aug 2001, 182:207-214.
54. Chen Y., Kuchroo V., Inobe J., Hafler D., Weiner H. Regulatory T cell clones induced by oral tolerance: suppression of autoimmune encephalomyelitis. Science 1994, 265(5176):1237-1240.
55. Faria A., Weiner H. Oral tolerance: therapeutic implications for autoimmune diseases. Clin Dev Immunol 2006, 13(2-4):143-157.
56. Carrier Y., Yuan J., Kuchroo V.K., Weiner H.L. Th3 cells in peripheral tolerance. I. Induction of Foxp3-positive regulatory T cells by Th3 cells derived from TGF-beta T cell-transgenic mice. J Immunol Jan 1 2007, 178(1):179-185.
57. Fowlkes B., Kruisbeek A., Ton-That H., Weston M., Coligan J., Schwartz R., et al. A novel population of T-cell receptor alpha beta-bearing thymocytes which predominantly expresses a single V beta gene family. Nature 1987, 329(6136):251-254.
58. Fischer K., Voelkl S., Heymann J., Przybylski G.K., Mondal K., Laumer M., et al. Isolation and characterization of human antigen-specific TCR alpha beta+ CD4(-)CD8- double-negative regulatory T cells. Blood Apr 1 2005, 105(7):2828-2835.
59. Ford M.S., Zhang Z.X., Chen W., Zhang L. Double-negative T regulatory cells can develop outside the thymus and do not mature from CD8+ T cell precursors. J Immunol Sep 1 2006, 177(5):2803-2809.
60. Zhang D., Yang W., Degauque N., Tian Y., Mikita A., Zheng X.X. New differentiation pathway for double-negative regulatory T cells that regulates the magnitude of immune responses. Blood May 1 2007, 109(9):4071-4079.
61. He K., Ma Y., Wang S., Min W., Zhong R., Jevnikar A., et al. Donor double-negative Treg promote allogeneic mixed chimerism and tolerance. Eur J Immunol 2007, 37(12):3455-3466.
62. Ford McIntyre M., Gao J., Li X., Naeini B., Zhang L. Consequences of double negative regulatory T cell and antigen presenting cell interaction on immune response suppression. Int Immunopharmacol 2010, 11(5):597-603.
63. Gao J., McIntyre M., Juvet S., Diao J., Li X., Vanama R., et al. Regulation of antigen-expressing dendritic cells by double negative regulatory T cells. Eur J Immunol 2011, 41(9):2699-2708.
64. Hill M., Thebault P., Segovia M., Louvet C., Bériou G., Tilly G., et al. Cell therapy with autologous tolerogenic dendritic cells induces allograft tolerance through interferon-gamma and Epstein-Barr virus-induced gene 3. Am J Transplant 2011, 11(10):2036-2045.
65. Jiang H., Braunstein N., Yu B., Winchester R., Chess L. CD8+ T cells control the TH phenotype of MBP-reactive CD4+ T cells in EAE mice. Proc Natl Acad Sci U S A 2001, 98(11):6301-6306.
66. Jiang H., Canfield S., Gallagher M., Jiang H., Jiang Y., Zheng Z., et al. HLA-E-restricted regulatory CD8(+) T cells are involved in development and control of human autoimmune type 1 diabetes. J Clin Invest 2010, 120(10):3641-3650.
67. Wei S., Kryczek I., Zou L., Daniel B., Cheng P., Mottram P., et al. Plasmacytoid dendritic cells induce CD8+ regulatory T cells in human ovarian carcinoma. Cancer Res Jun 15 2005, 65(12):5020-5026.
68. Suzuki M., Jagger A., Konya C., Shimojima Y., Pryshchep S., Goronzy J., et al. CD8+CD45RA+CCR7+FOXP3+ T cells with immunosuppressive properties: a novel subset of inducible human regulatory T cells. J Immunol 2012, 189(5):2118-2130.
69. Han Y., Guo Q., Zhang M., Chen Z., Cao X. CD69+ CD4+ CD25- T cells, a new subset of regulatory T cells, suppress T cell proliferation through membrane-bound TGF-beta 1. J Immunol 2009, 182(1):111-120.
70. Umansky V., Sevko A. Tumor microenvironment and myeloid-derived suppressor cells. Cancer Micrenviron Dec 2012, (in press). 10.1007/s12307-012-0126-7.
71. Youn J., Gabrilovich D. The biology of myeloid-derived suppressor cells: the blessing and the curse of morphological and functional heterogeneity. Eur J Immunol 2010, 40(11):2969-2975.
72. Finn O. Immuno-oncology: understanding the function and dysfunction of the immune system in cancer. Ann Oncol 2012, 23(Suppl. 8):viii6-viii9.
73. Bates G.J., Fox S.B., Han C., Leek R.D., Garcia J.F., Harris A.L., et al. Quantification of regulatory T cells enables the identification of high-risk breast cancer patients and those at risk of late relapse. J Clin Oncol Dec 1 2006, 24(34):5373-5380.
74. Wang Z., Yang B., Liu H., Hu Y., Yang J., Wu L., et al. Regulatory T cells increase in breast cancer and in stage IV breast cancer. Cancer Immunol Immunother 2012, 61(6):911-916.
75. Tan W., Zhang W., Strasner A., Grivennikov S., Cheng J., Hoffman R., et al. Tumour-infiltrating regulatory T cells stimulate mammary cancer metastasis through RANKL-RANK signalling. Nature 2011, 470(7335):548-553.
76. Ramos R., Chin L., Dos Santos A., Bergami-Santos P., Laginha F., Barbuto J. Monocyte-derived dendritic cells from breast cancer patients are biased to induce CD4+CD25+Foxp3+ regulatory T cells. J Leukoc Biol 2012, 92(3):673-682.
77. Wang J., Cai D., Ma B., Wu G., Wu J. Skewing the balance of regulatory T-cells and T-helper 17 cells in breast cancer patients. J Int Med Res 2011, 39(3):691-701.
78. Curiel T.J., Coukos G., Zou L., Alvarez X., Cheng P., Mottram P., et al. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med Sep 2004, 10(9):942-949.
79. Wolf D., Wolf A., Rumpold H., Fiegl H., Zeimet A., Muller-Holzner E., et al. The expression of the regulatory T cell-specific forkhead box transcription factor FoxP3 is associated with poor prognosis in ovarian cancer. Clin Cancer Res 2005, 11(23):8326-8331.
80. Fialová A., Partlová S., Sojka L., Hromádková H., Brtnický T., Fučíková J., et al. Dynamics of T-cell infiltration during the course of ovarian cancer: The gradual shift from a Th17 effector cell response to a predominant infiltration by regulatory T-cells. Int J Cancer 2012, 10.1002/ijc.27759.
81. Kryczek I., Banerjee M., Cheng P., Vatan L., Szeliga W., Wei S., et al. Phenotype, distribution, generation, and functional and clinical relevance of Th17 cells in the human tumor environments. Blood 2009, 114(6):1141-1149.
82. Miller A.M., Lundberg K., Ozenci V., Banham A.H., Hellstrom M., Egevad L., et al. CD4+CD25high T cells are enriched in the tumor and peripheral blood of prostate cancer patients. J Immunol Nov 15 2006, 177(10):7398-7405.
83. Yokokawa J., Cereda V., Remondo C., Gulley J., Arlen P., Schlom J., et al. Enhanced functionality of CD4+CD25(high)FoxP3+ regulatory T cells in the peripheral blood of patients with prostate cancer. Clin Cancer Res 2008, 14(4):1032-1040.
84. Vergati M., Cereda V., Madan R., Gulley J., Huen N., Rogers C., et al. Analysis of circulating regulatory T cells in patients with metastatic prostate cancer pre- versus post-vaccination. Cancer Immunol Immunother 2011, 60(2):197-206.
85. Zhao E., Wang L., Dai J., Kryczek I., Wei S., Vatan L., et al. Regulatory T cells in the bone marrow microenvironment in patients with prostate cancer. Oncoimmunology 2012, 1(2):152-161.
86. Ling K.L., Pratap S.E., Bates G.J., Singh B., Mortensen N.J., George B.D., et al. Increased frequency of regulatory T cells in peripheral blood and tumour infiltrating lymphocytes in colorectal cancer patients. Cancer Immun 2007, 7:7.
87. Lin Y., Mahalingam J., Chiang J., Su P., Chu Y., Lai H., et al. Activated but not resting regulatory T cells accumulated in tumor microenvironment and correlated with tumor progression in patients with colorectal cancer. Int J Cancer 2012, [Epub ahead of print]. 10.1002/ijc.27784.
88. Griffiths R.W., Elkord E., Gilham D.E., Ramani V., Clarke N., Stern P.L., et al. Frequency of regulatory T cells in renal cell carcinoma patients and investigation of correlation with survival. Cancer Immunol Immunother Nov 2007, 56(11):1743-1753.
89. Finke J., Rini B., Ireland J., Rayman P., Richmond A., Golshayan A., et al. Sunitinib reverses type-1 immune suppression and decreases T-regulatory cells in renal cell carcinoma patients. Clin Cancer Res 2008, 14(20):6674-6682.
90. Adotevi O., Pere H., Ravel P., Haicheur N., Badoual C., Merillon N., et al. A decrease of regulatory T cells correlates with overall survival after sunitinib-based antiangiogenic therapy in metastatic renal cancer patients. J Immunother 2010, 33(9):991-998.
91. Jensen H., Donskov F., Nordsmark M., Marcussen N., von der Maase H. Increased intratumoral FOXP3-positive regulatory immune cells during interleukin-2 treatment in metastatic renal cell carcinoma. Clin Cancer Res 2009, 15(3):1052-1058.
92. Baumgartner J., Wilson C., Palmer B., Richter D., Banerjee A., McCarter M. Melanoma induces immunosuppression by up-regulating FOXP3(+) regulatory T cells. J Surg Res Jul 2007, 141(1):72-77.
93. Viguier M., Lemaitre F., Verola O., Cho M.S., Gorochov G., Dubertret L., et al. Foxp3 expressing CD4+CD25(high) regulatory T cells are overrepresented in human metastatic melanoma lymph nodes and inhibit the function of infiltrating T cells. J Immunol Jul 15 2004, 173(2):1444-1453.
94. Ahmadzadeh M., Felipe-Silva A., Heemskerk B., Powell D.J., Wunderlich J.R., Merino M.J., et al. FOXP3 expression accurately defines the population of intratumoral regulatory T cells that selectively accumulate in metastatic melanoma lesions. Blood Sep 26 2008, 112(13):4953-4960.
95. Martin-Orozco N., Li Y., Wang Y., Liu S., Hwu P., Liu Y., et al. Melanoma cells express ICOS ligand to promote the activation and expansion of T-regulatory cells. Cancer Res 2010, 70(23):9581-9590.
96. Gjerdrum L.M., Woetmann A., Odum N., Burton C.M., Rossen K., Skovgaard G.L., et al. FOXP3+ regulatory T cells in cutaneous T-cell lymphomas: association with disease stage and survival. Leukemia Dec 2007, 21(12):2512-2518.
97. Lee N., Song E., Jang K., Choi H., Moon W., Kwon K., et al. Prognostic impact of tumor infiltrating FOXP3 positive regulatory T cells in diffuse large B-cell lymphoma at diagnosis. Leuk Lymphoma 2008, 49(2):247-256.
98. Tzankov A., Meier C., Hirschmann P., Went P., Pileri S.A., Dirnhofer S. Correlation of high numbers of intratumoral FOXP3+ regulatory T cells with improved survival in germinal center-like diffuse large B-cell lymphoma, follicular lymphoma and classical Hodgkin's lymphoma. Haematologica 2008, 93:193-200.
99. Barath S., Aleksza M., Keresztes K., Toth J., Sipka S., Szegedi G., et al. Immunoregulatory T cells in the peripheral blood of patients with Hodgkin's lymphoma. Acta Haematol 2006, 116(3):181-185.
100. Marshall N.A., Culligan D.J., Tighe J., Johnston P.W., Barker R.N., Vickers M.A. The relationships between Epstein-Barr virus latent membrane protein 1 and regulatory T cells in Hodgkin's lymphoma. Exp Hematol Apr 2007, 35(4):596-604.
101. Baumforth K., Birgersdotter A., Reynolds G., Wei W., Kapatai G., Flavell J., et al. Expression of the Epstein-Barr virus-encoded Epstein-Barr virus nuclear antigen 1 in Hodgkin's lymphoma cells mediates up-regulation of CCL20 and the migration of regulatory T cells. Am J Pathol 2008, 173(1):195-204.
102. Schreck S., Friebel D., Buettner M., Distel L., Grabenbauer G., Young L., et al. Prognostic impact of tumour-infiltrating Th2 and regulatory T cells in classical Hodgkin lymphoma. Hematol Oncol 2009, 17(1):31-39.
103. Mittal S., Marshall N., Duncan L., Culligan D., Barker R., Vickers M. Local and systemic induction of CD4+CD25+ regulatory T-cell population by non-Hodgkin lymphoma. Blood 2008, 111(1):5359-5370.
104. Han Y., Wu J., Bi L., Xiong S., Gao S., Yin L., et al. Malignant B cells induce the conversion of CD4+CD25- T cells to regulatory T cells in B-cell non-Hodgkin lymphoma. PLoS One 2011, 6(12):e28649.
105. Elpek K., Lacelle C., Singh N., Yolcu E., Shirwan H. CD4+CD25+ T regulatory cells dominate multiple immune evasion mechanisms in early but not late phases of tumor development in a B cell lymphoma model. J Immunol 2007, 178(11):6840-6848.
106. Serafini P., Mgebroff S., Noonan K., Borrello I. Myeloid-derived suppressor cells promote cross-tolerance in B-cell lymphoma by expanding regulatory T cells. Cancer Res 2008, 68(13):5439-5449.
107. Yang Z., Novak A., Ziesmer S., Witzig T., Ansell S. Malignant B cells skew the balance of regulatory T cells and TH17 cells in B-cell non-Hodgkin's lymphoma. Cancer Res 2009, 69(13):5522-5530.
108. Di Nicola M., Zappasodi R., Carlo-Stella C., Mortarini R., Pupa S., Magni M., et al. Vaccination with autologous tumor-loaded dendritic cells induces clinical and immunologic responses in indolent B-cell lymphoma patients with relapsed and measurable disease: a pilot study. Blood 2009, 113(1):18-27.
109. Lindqvist C., Christiansson L., Simonsson B., Enblad G., Olsson-Strömberg U., Loskog A. T regulatory cells control T-cell proliferation partly by the release of soluble CD25 in patients with B-cell malignancies. Immunology 2010, 131(3):371-376.
110. Wang J., Ke X. The four types of Tregs in malignant lymphomas. J Hematol Oncol 2011, 4(50). 10.1186/756-8722-4-50.
111. Beyer M., Kochanek M., Darabi K., Popov A., Jensen M., Endl E., et al. Reduced frequencies and suppressive function of CD4+CD25hi regulatory T cells in patients with chronic lymphocytic leukemia after therapy with fludarabine. Blood Sep 15 2005, 106(6):2018-2025.
112. D'Arena G., Laurenti L., Minervini M., Deaglio S., Bonello L., De Martino L., et al. Regulatory T-cell number is increased in chronic lymphocytic leukemia patients and correlates with progressive disease. Leuk Res 2011, 35(3):363-368.
113. Jak M., Mous R., Remmerswaal E., Spijker R., Jaspers A., Yagüe A., et al. Enhanced formation and survival of CD4+ CD25hi Foxp3+ T-cells in chronic lymphocytic leukemia. Leuk Lymphoma 2009, 50(5):788-801.
114. Ramsay A.G., Johnson A.J., Lee A.M., Gorgun G., Le Dieu R., Blum W., et al. Chronic lymphocytic leukemia T cells show impaired immunological synapse formation that can be reversed with an immunomodulating drug. J Clin Invest Jul 2008, 118(7):2427-2437. [Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't].
115. Kordasti S.Y., Ingram W., Hayden J., Darling D., Barber L., Afzali B., et al. CD4+CD25high Foxp3+ regulatory T cells in myelodysplastic syndrome (MDS). Blood Aug 1 2007, 110(3):847-850.
116. Hamdi W., Ogawara H., Handa H., Tsukamoto N., Nojima Y., Murakami H. Clinical significance of regulatory T cells in patients with myelodysplastic syndrome. Eur J Haematol 2009, 82(3):201-207.
117. Shenghui Z., Yixiang H., Jianbo W., Kang Y., Laixi B., Yan Z., et al. Elevated frequencies of CD4+ CD25+ CD127lo regulatory T cells is associated to poor prognosis in patients with acute myeloid leukemia. Int J Cancer 2010, 129(6):1373-1381.
118. Szczepanski M., Szajnik M., Czystowska M., Mandapathil M., Strauss L., Welsh A., et al. Increased frequency and suppression by regulatory T cells in patients with acute myelogenous leukemia. Clin Cancer Res 2009, 15(10):3325-3332.
119. Curti A., Pandolfi S., Valzasina B., Aluigi M., Isidori A., Ferri E., et al. Modulation of tryptophan catabolism by human leukemic cells results in the conversion of CD25- into CD25+ T regulatory cells. Blood Apr 1 2007, 109(7):2871-2877.
120. Kanakry C., Hess A., Gocke C., Thoburn C., Kos F., Meyer C., et al. Early lymphocyte recovery after intensive timed sequential chemotherapy for acute myelogenous leukemia: peripheral oligoclonal expansion of regulatory T cells. Blood 2011, 117(2):608-617.
121. Harrison S.J., Cook G. Immunotherapy in multiple myeloma - possibility or probability?. Br J Haematol Aug 2005, 130(3):344-362.
122. Robertson J.D., Nagesh K., Jowitt S.N., Dougal M., Anderson H., Mutton K., et al. Immunogenicity of vaccination against influenza, Streptococcus pneumoniae and Haemophilus influenzae type B in patients with multiple myeloma. Br J Cancer Apr 2000, 82(7):1261-1265.
123. Cook G., Campbell J.D. Immune regulation in multiple myeloma: the host-tumour conflict. Blood Rev Sep 1999, 13(3):151-162.
124. Cook G., Campbell J.D., Carr C.E., Boyd K.S., Franklin I.M. Transforming growth factor beta from multiple myeloma cells inhibits proliferation and IL-2 responsiveness in T lymphocytes. J Leukoc Biol Dec 1999, 66(6):981-988.
125. Kim R., Emi M., Tanabe K. Cancer immunosuppression and autoimmune disease: beyond immunosuppressive networks for tumour immunity. Immunology Oct 2006, 119(2):254-264.
126. Ratta M., Fagnoni F., Curti A., Vescovini R., Sansoni P., Oliviero B., et al. Dendritic cells are functionally defective in multiple myeloma: the role of interleukin-6. Blood Jul 1 2002, 100(1):230-237. [Research Support, Non-U.S. Gov't].
127. Brown R.D., Pope B., Murray A., Esdale W., Sze D.M., Gibson J., et al. Dendritic cells from patients with myeloma are numerically normal but functionally defective as they fail to up-regulate CD80 (B7-1) expression after huCD40LT stimulation because of inhibition by transforming growth factor-beta1 and interleukin-10. Blood Nov 15 2001, 98(10):2992-2998. [Research Support, Non-U.S. Gov't].
128. Brown R., Murray A., Pope B., Sze D.M., Gibson J., Ho P.J., et al. Either interleukin-12 or interferon-gamma can correct the dendritic cell defect induced by transforming growth factor beta in patients with myeloma. Br J Haematol Jun 2004, 125(6):743-748. [Research Support, Non-U.S. Gov't].
129. -/low myeloid-derived suppressor cells and decreased level of dendritic cells in patients with multiple myeloma. Scand J Immunol 2010, 72(6):540-547.
130. Wang S., Yang J., Qian J., Wezeman M., Kwak L.W., Yi Q. Tumor evasion of the immune system: inhibiting p38 MAPK signaling restores the function of dendritic cells in multiple myeloma. Blood Mar 15 2006, 107(6):2432-2439.
131. Okunishi K., Dohi M., Nakagome K., Tanaka R., Mizuno S., Matsumoto K., et al. A novel role of hepatocyte growth factor as an immune regulator through suppressing dendritic cell function. J Immunol Oct 1 2005, 175(7):4745-4753. [Research Support, Non-U.S. Gov't].
132. Singhal E., Kumar P., Sen P. A novel role for Bruton's tyrosine kinase in hepatocyte growth factor-mediated immunoregulation of dendritic cells. J Biol Chem Sep 16 2011, 286(37):32054-32063. [Research Support, Non-U.S. Gov't].
133. Cao Y., Luetkens T., Kobold S., Hildebrandt Y., Gordic M., Lajmi N., et al. The cytokine/chemokine pattern in the bone marrow environment of multiple myeloma patients. Exp Hematol Oct 2010, 38(10):860-867. [Research Support, Non-U.S. Gov't].
134. Rutella S., Bonanno G., Procoli A., Mariotti A., de Ritis D.G., Curti A., et al. Hepatocyte growth factor favors monocyte differentiation into regulatory interleukin (IL)-10++IL-12low/neg accessory cells with dendritic-cell features. Blood Jul 1 2006, 108(1):218-227. [Research Support, Non-U.S. Gov't].
135. Gabrilovich D., Ishida T., Oyama T., Ran S., Kravtsov V., Nadaf S., et al. Vascular endothelial growth factor inhibits the development of dendritic cells and dramatically affects the differentiation of multiple hematopoietic lineages in vivo. Blood Dec 1 1998, 92(11):4150-4166. [Research Support, U.S. Gov't, P.H.S.].
136. Xie J., Wang Y., Freeman M.E., Barlogie B., Yi Q. Beta 2-microglobulin as a negative regulator of the immune system: high concentrations of the protein inhibit in vitro generation of functional dendritic cells. Blood May 15 2003, 101(10):4005-4012. [Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, P.H.S.].
137. Gorczynski R.M., Lee L., Boudakov I. Augmented induction of CD4+CD25+ Treg using monoclonal antibodies to CD200R. Transplantation May 15 2005, 79(9):1180-1183.
138. Moreaux J., Hose D., Reme T., Jourdan E., Hundemer M., Legouffe E., et al. CD200 is a new prognostic factor in multiple myeloma. Blood Dec 15 2006, 108(13):4194-4197. [Comparative Study Research Support, Non-U.S. Gov't].
139. Olteanu H., Harrington A.M., Kroft S.H. Immunophenotypic stability of CD200 expression in plasma cell myeloma. Am J Clin Pathol Jun 2012, 137(6):1013-1014. [Comment Letter].
140. Banerjee D.K., Dhodapkar M.V., Matayeva E., Steinman R.M., Dhodapkar K.M. Expansion of FOXP3high regulatory T cells by human dendritic cells (DCs) in vitro and after injection of cytokine-matured DCs in myeloma patients. Blood Oct 15 2006, 108(8):2655-2661.
141. Nair J., Carlson L., Koorella C., Rozanski C., Byrne G., Bergsagel P., et al. CD28 expressed on malignant plasma cells induces a prosurvival and immunosuppressive microenvironment. J Immunol 2011, 187(3):1243-1253.
142. Mills K., Cawley J. Abnormal monoclonal antibody-defined helper/suppressor T-cell subpopulations in multiple myeloma: relationship to treatment and clinical stage. Br J Haematol 1983, 53(2):271-275.
143. Ogawara H., Handa H., Yamazaki T., Toda T., Yoshida K., Nishimoto N., et al. High Th1/Th2 ratio in patients with multiple myeloma. Leuk Res 2005, 29(2):135-140.
144. San Miguel J., González M., Gascón A., Moro M., Hernández J., Ortega F., et al. Lymphoid subsets and prognostic factors in multiple myeloma. Cooperative Group for the Study of Monoclonal Gammopathies. Br J Haematol 1992, 80(3):305-309.
145. Mosmann T.R., Coffman R.L. TH1 and TH2 cells: different patterns of lymphokine secretion lead to different functional properties. Annu Rev Immunol 1989, 7:145-173. [Review].
146. Mariani S., Coscia M., Even J., Peola S., Foglietta M., Boccadoro M., et al. Severe and long-lasting disruption of T-cell receptor diversity in human myeloma after high-dose chemotherapy and autologous peripheral blood progenitor cell infusion. Br J Haematol Jun 2001, 113(4):1051-1059. [Comparative Study Research Support, Non-U.S. Gov't].
147. Sze D.M., Giesajtis G., Brown R.D., Raitakari M., Gibson J., Ho J., et al. Clonal cytotoxic T cells are expanded in myeloma and reside in the CD8(+)CD57(+)CD28(-) compartment. Blood Nov 1 2001, 98(9):2817-2827. [Research Support, Non-U.S. Gov't].
148. Thomas D.A., Massague J. TGF-beta directly targets cytotoxic T cell functions during tumor evasion of immune surveillance. Cancer Cell Nov 2005, 8(5):369-380. [Research Support, Non-U.S. Gov't].
149. Mozaffari F., Hansson L., Kiaii S., Ju X., Rossmann E.D., Rabbani H., et al. Signalling molecules and cytokine production in T cells of multiple myeloma-increased abnormalities with advancing stage. Br J Haematol Feb 2004, 124(3):315-324. [Research Support, Non-U.S. Gov't].
150. Osterborg A., Yi Q., Bergenbrant S., Holm G., Lefvert A.K., Mellstedt H. Idiotype-specific T cells in multiple myeloma stage I: an evaluation by four different functional tests. Br J Haematol Jan 1995, 89(1):110-116. [Research Support, Non-U.S. Gov't].
151. Dhodapkar M.V., Krasovsky J., Osman K., Geller M.D. Vigorous premalignancy-specific effector T cell response in the bone marrow of patients with monoclonal gammopathy. J Exp Med Dec 1 2003, 198(11):1753-1757. [Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, P.H.S.].
152. Wen Y.J., Barlogie B., Yi Q. Idiotype-specific cytotoxic T lymphocytes in multiple myeloma: evidence for their capacity to lyse autologous primary tumor cells. Blood Mar 15 2001, 97(6):750-755. [Research Support, Non-U.S. Gov't].
153. Bogen B., Ruffini P.A., Corthay A., Fredriksen A.B., Froyland M., Lundin K., et al. Idiotype-specific immunotherapy in multiple myeloma: suggestions for future directions of research. Haematologica Jul 2006, 91(7):941-948.
154. Haslett P.A., Corral L.G., Albert M., Kaplan G. Thalidomide costimulates primary human T lymphocytes, preferentially inducing proliferation, cytokine production, and cytotoxic responses in the CD8+ subset. J Exp Med Jun 1 1998, 187(11):1885-1892. [Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, P.H.S.].
155. Li Y., Bendandi M., Deng Y., Dunbar C., Munshi N., Jagannath S., et al. Tumor-specific recognition of human myeloma cells by idiotype-induced CD8(+) T cells. Blood Oct 15 2000, 96(8):2828-2833.
156. Goodyear O., Piper K., Khan N., Starczynski J., Mahendra P., Pratt G., et al. CD8+ T cells specific for cancer germline gene antigens are found in many patients with multiple myeloma, and their frequency correlates with disease burden. Blood Dec 15 2005, 106(13):4217-4224. [Research Support, Non-U.S. Gov't].
157. Choi C., Witzens M., Bucur M., Feuerer M., Sommerfeldt N., Trojan A., et al. Enrichment of functional CD8 memory T cells specific for MUC1 in bone marrow of patients with multiple myeloma. Blood Mar 1 2005, 105(5):2132-2134.
158. Spisek R., Kukreja A., Chen L.C., Matthews P., Mazumder A., Vesole D., et al. Frequent and specific immunity to the embryonal stem cell-associated antigen SOX2 in patients with monoclonal gammopathy. J Exp Med Apr 16 2007, 204(4):831-840. [Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't].
159. Beyer M., Kochanek M., Giese T., Endl E., Weihrauch M.R., Knolle P.A., et al. In vivo peripheral expansion of naive CD4+CD25high FoxP3+ regulatory T cells in patients with multiple myeloma. Blood May 15 2006, 107(10):3940-3949.
160. Feyler S., von Lilienfeld-Toal M., Jarmin S., Marles L., Rawstron A., Ashcroft A.J., et al. CD4(+)CD25(+)FoxP3(+) regulatory T cells are increased whilst CD3(+)CD4(-)CD8(-)alphabetaTCR(+) double negative T cells are decreased in the peripheral blood of patients with multiple myeloma which correlates with disease burden. Br J Haematol Mar 2009, 144(5):686-695. [Comparative Study Research Support, Non-U.S. Gov't].
161. Fiore F., Nuschak B., Peola S., Mariani S., Muraro M., Foglietta M., et al. Exposure to myeloma cell lysates affects the immune competence of dendritic cells and favors the induction of Tr1-like regulatory T cells. Eur J Immunol Apr 2005, 35(4):1155-1163.
162. Atanackovic D., Cao Y., Luetkens T., Panse J., Faltz C., Arfsten J., et al. CD4+CD25+FOXP3+ T regulatory cells reconstitute and accumulate in the bone marrow of patients with multiple myeloma following allogeneic stem cell transplantation. Haematologica 2008, 93(3):423-430.
163. Mellor A.L., Baban B., Chandler P., Marshall B., Jhaver K., Hansen A., et al. Cutting edge: induced indoleamine 2,3 dioxygenase expression in dendritic cell subsets suppresses T cell clonal expansion. J Immunol Aug 15 2003, 171(4):1652-1655. [Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, P.H.S.].
164. Borsellino G., Kleinewietfeld M., Di Mitri D., Sternjak A., Diamantini A., Giometto R., et al. Expression of ectonucleotidase CD39 by Foxp3+ Treg cells: hydrolysis of extracellular ATP and immune suppression. Blood Aug 15 2007, 110(4):1225-1232. [Research Support, Non-U.S. Gov't].
165. von Boehmer H. Mechanisms of suppression by suppressor T cells. Nat Immunol Apr 2005, 6(4):338-344. [Research Support, U.S. Gov't, P.H.S. Review].
166. Feyler S., Scott G.B., Parrish C., Jarmin S., Evans P., Short M., et al. Tumour cell generation of inducible regulatory T-cells in multiple myeloma is contact-dependent and antigen-presenting cell-independent. PLoS One 2012, 7(5):e35981.
167. Brown R., Kabani K., Favaloro J., Yang S., Ho P.J., Gibson J., et al. CD86+ or HLA-G+ myeloma cells are associated with poor prognosis and once acquired by trogocytosis create novel Tregacq cells. Blood Jun 15 2012, 120(10):2055-2063.
168. Condomines M., Quittet P., Lu Z.Y., Nadal L., Latry P., Lopez E., et al. Functional regulatory T cells are collected in stem cell autografts by mobilization with high-dose cyclophosphamide and granulocyte colony-stimulating factor. J Immunol Jun 1 2006, 176(11):6631-6639.
169. Atanackovic D., Cao Y., Luetkens T., Panse J., Faltz C., Arfsten J., et al. CD4+CD25+FOXP3+ T regulatory cells reconstitute and accumulate in the bone marrow of patients with multiple myeloma following allogeneic stem cell transplantation. Haematologica Mar 2008, 93(3):423-430.
170. Cook G., Bird J.M., Marks D.I. In pursuit of the allo-immune response in multiple myeloma: where do we go from here?. Bone Marrow Transplant Jan 2009, 43(2):91-99.
171. Rosenblatt J., Vasir B., Uhl L., Blotta S., Macnamara C., Somaiya P., et al. Vaccination with dendritic cell/tumor fusion cells results in cellular and humoral antitumor immune responses in patients with multiple myeloma. Blood Jan 13 2011, 117(2):393-402. [Clinical Trial, Phase I Research Support, N.I.H., Extramural].
172. Rapoport A.P., Stadtmauer E.A., Aqui N., Badros A., Cotte J., Chrisley L., et al. Restoration of immunity in lymphopenic individuals with cancer by vaccination and adoptive T-cell transfer. Nat Med Nov 2005, 11(11):1230-1237. [Clinical Trial, Phase I Clinical Trial, Phase II Comparative Study Randomized Controlled Trial Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't].
173. Chen Y.L., Chang M.C., Chen C.A., Lin H.W., Cheng W.F., Chien C.L. Depletion of regulatory T lymphocytes reverses the imbalance between pro- and anti-tumor immunities via enhancing antigen-specific T cell immune responses. PLoS One 2012, 7(10):e47190. [Research Support, Non-U.S. Gov't].
174. Knueppel A., Lange S., Altmann S., Sekora A., Knuebel G., Vogel H., et al. Upfront denileukin diftitox as in vivo regulatory T-cell depletion in order to enhance vaccination effects in a canine allogeneic hematopoietic stem cell transplantation model. Vet Immunol Immunopathol Jan 15 2012, 145(1-2):233-240. [Research Support, Non-U.S. Gov't].
175. Touil S., Rosenzwajg M., Landau D.A., Le Corvoisier P., Frederic C., Klatzmann D., et al. Depletion of T regulatory cells through selection of CD127-positive cells results in a population enriched in memory T cells: implications for anti-tumor cell therapy. Haematologica Nov 2012, 97(11):1678-1685. [Research Support, Non-U.S. Gov't].
176. Mattarollo S.R., Steegh K., Li M., Duret H., Foong Ngiow S., Smyth M.J. Transient Foxp3(+) regulatory T-cell depletion enhances therapeutic anticancer vaccination targeting the immune-stimulatory properties of NKT cells. Immunol Cell Biol Jan 2013, 91(1):105-114.
177. Lonial S., Vij R., Harousseau J.L., Facon T., Moreau P., Mazumder A., et al. Elotuzumab in combination with lenalidomide and low-dose dexamethasone in relapsed or refractory multiple myeloma. J Clin Oncol Jun 1 2012, 30(16):1953-1959. [Clinical Trial, Phase I Research Support, Non-U.S. Gov't.
178. Richardson P.G., Lonial S., Jakubowiak A.J., Harousseau J.L., Anderson K.C. Monoclonal antibodies in the treatment of multiple myeloma. Br J Haematol Jul 21 2011, 154(6):745-754.
179. Verbon A., Juffermans N.P., Speelman P., van Deventer S.J., ten Berge I.J., Guchelaar H.J., et al. A single oral dose of thalidomide enhances the capacity of lymphocytes to secrete gamma interferon in healthy humans. Antimicrob Agents Chemother Sep 2000, 44(9):2286-2290. [Clinical Trial Research Support, Non-U.S. Gov't].
180. Davies F., Raje N., Hideshima T., Lentzsch S., Young G., Tai Y., et al. Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma. Blood 2001, 98(1):210-216.
181. Marriott J., Clarke I., Dredge K., Muller G., Stirling D., Dalgleish A. Thalidomide and its analogues have distinct and opposing effects on TNF-alpha and TNFR2 during co-stimulation of both CD4(+) and CD8(+) T cells. Clin Exp Immunol 2002, 130(1):75-84.
182. LeBlanc R., Hideshima T., Catley L.P., Shringarpure R., Burger R., Mitsiades N., et al. Immunomodulatory drug costimulates T cells via the B7-CD28 pathway. Blood Mar 1 2004, 103(5):1787-1790. [Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, Non-P.H.S. Research Support, U.S. Gov't, P.H.S.].
183. Hayashi T., Hideshima T., Akiyama M., Podar K., Yasui H., Raje N., et al. Molecular mechanisms whereby immunomodulatory drugs activate natural killer cells: clinical application. Br J Haematol Jan 2005, 128(2):192-203. [Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, P.H.S.].
184. Chang D.H., Liu N., Klimek V., Hassoun H., Mazumder A., Nimer S.D., et al. Enhancement of ligand-dependent activation of human natural killer T cells by lenalidomide: therapeutic implications. Blood Jul 15 2006, 108(2):618-621. [Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't].
185. Richter J., Neparidze N., Zhang L., Nair S., Monesmith T., Sundaram R., et al. Clinical regressions and broad immune activation following combination therapy targeting human NKT cells in myeloma. Blood 2013 Jan 17, 121(3):423-430.